Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991
- 10 May 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (14), 2460-2466
- https://doi.org/10.1200/jco.2009.24.6264
Abstract
Conflicting data have been reported concerning the prognostic value of autoimmune antibodies in patients with melanoma treated with adjuvant interferon alfa-2b (IFN). We evaluated the prognostic significance of autoantibodies in the European Organisation for Research and Treatment of Cancer 18991 trial, comparing long-term administration of pegylated IFN (PEG-IFN) with observation. Anticardiolipin, antithyroglobulin, and antinuclear antibodies were determined by enzyme-linked immunosorbent assays in 296 patients before random assignment and every 6 months after random assignment for up to 5 years. Prognostic impact of autoantibodies on recurrence-free survival (RFS) was assessed using the following three Cox models: a model that considered autoantibody appearance as a time-independent variable (model 1); a model that considered a patient to be autoantibody positive from the first positive test (model 2); and a model in which the most recent autoantibody test was used to define the status of the patient (model 3). Patients who were autoantibody negative at baseline were analyzed (n = 220). Occurrence of autoantibodies during follow-up was higher in the PEG-IFN–treated patients (18% in the observation arm v 52% in the PEG-IFN arm). Autoantibody appearance was of prognostic importance by using model 1 (hazard ratio [HR] = 0.56; 95% CI, 0.36 to 0.87; P = .01). However, when guarantee-time bias was taken into account using model 2 (HR = 1.19; 95% CI, 0.75 to 1.88; P = .46) or method 3 (HR = 1.14; 95% CI, 0.71 to 1.83; P = .59), significance was lost. Results were similar when treatment groups were analyzed separately. Appearance of autoimmune antibodies is neither a prognostic nor a predictive factor for improved outcome in patients with melanoma treated with PEG-IFN.Keywords
This publication has 26 references indexed in Scilit:
- Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant InterferonJNCI Journal of the National Cancer Institute, 2009
- Severe Systemic Lupus Erythematosus Induced by Antiviral Treatment for Hepatitis CJCR: Journal of Clinical Rheumatology, 2008
- Does Adjuvant Vaccine Therapy Really Have Activity in Malignant Melanoma?Journal of Clinical Oncology, 2007
- A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?Acta Diabetologica, 2007
- Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alphaInternational Journal of Cancer, 2007
- Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis.Journal of Gastroenterology and Hepatology, 2006
- Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis CArquivos de Gastroenterologia, 2004
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsCancer Treatment Reviews, 2003
- Range of antinuclear antibodies in “healthy” individualsArthritis & Rheumatism, 1997
- Is anticardiolipin activity a cross‐reaction of anti‐DNA or a separate entity?Arthritis & Rheumatism, 1987